Currently, the first-line treatment for HER2-positive metastatic BC is trastuzumab and pertuzumab plus docetaxel 71, while the antibody-drug conjugate trastuzumab emtansine (T-DM1) is used as second-line therapy 72 (Figure 1). The gene discussed is ERBB2; the disease is breast cancer.